This class of drugs are now emerging as new potential therapeutics for AS, after the successful results obtained in phase 2 and phase 3 trials of tofacitinib (pan-JAK inhibitor), upadacitinib (selective JAK1 inhibitor) and filgotinib (selective JAK1 inhibitor) in AS
MS: Funding acquisition, Resources, Supervision, Validation, Writing review & editing
For detection of PDE, loading control -actin, as well as phosphorylated S6 ribosomal protein (2F9) (pS6P on S235/S236) and total S6 ribosomal protein (54D2) (tS6P), membranes were blocked with 5% milk in PBS-T for 1 h at room temperature, followed by washing, incubation with the primary antibody, anti-PDE (Invitrogen, PA5-22008, RRID: AB_11154288, 1:500), or anti- -actin (Abcam, ab8227, RRID:AB_2305186, 1: 5000), or anti-pS6P (Cell Signalling Technology, #4856, RRID: AB_2181037, 1:1000), or anti-tS6P (Cell Signalling Technology, #2317, RRID: AB_2238583, 1:500) overnight at 4 C and subsequently with horseradish peroxidase (HRP)-conjugated secondary antibodies (Invitrogen, #62-6520, RRID: AB_88369 for anti-mouse, 1:5000
Aplikacja miejscowa jest bezpieczniejsza ni iniekcje i daje dobre efekty w poprawie kondycji skry i redukcji zmarszczek